PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

July 10, 2001
Date

Linda Povinelli

#22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	B. Brett Finlay *et al.*
Application No.	:	09/189,415
Filed	:	November 10, 1998
For	:	HOST RECEPTOR FOR PATHOGENIC BACTERIA

Examiner	:	S. Devi
Art Unit	:	1645
Docket No.	:	482112.402
Date	:	July 10, 2001

Commissioner for Patents
Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents:

In response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 27, 2001, Applicants submit the following:

(1) Declaration regarding Sequence Listing;

(2) Paper copy of Sequence Listing (11 pages);

(3) Computer Readable Form of Sequence Listing; and

(4) Copy of Notice to Comply.

The enclosed Sequence Listing includes no new material and complies with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. Applicants respectfully submit that this application is now in compliance with 37 C.F.R. §§ 1.821-1.825 and WIPO Standard 25.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jeffrey C. Pepe, Ph.D.
Registration No. 46,985

Phone: (206) 622-4900
Fax: (206) 682-6031

JCP:lmp 193943

$ DAC
BOX ISEQ

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/189,415
Filing Date	November 10, 1998
First Named Inventor	B. Brett Finlay
Group Art Unit	1645
Examiner Name	S. Devi
Attorney Docket No.	482112.402

ENCLOSURES (*check all that apply*)

- [X] Fee Transmittal Form
  - [X] Fee Attached
- [ ] Amendment/Response
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [ ] Information Disclosure Statement; Form PTO-1449
- [ ] Cited References
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
- [ ] Response to Missing Parts/Incomplete Application
- [ ] Assignment Papers *(for an Application)*
- [ ] Drawing(s)
- [ ] Request for Corrected Filing Receipt
- [ ] Licensing-related Papers
- [X] Petition **TO REVIVE**
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation, Change of Correspondence Address
- [X] Declaration **re: Sequence Listing**
- [ ] Statement under 37 CFR 3.73(b)
- [ ] Terminal Disclaimer
- [ ] Small Entity Statement
- [ ] Request for Refund
- [ ] CD(s), Number of CD(s) _____
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- [ ] Proprietary Information
- [ ] Status Letter
- [X] Return Receipt Postcard
- [X] Additional Enclosure(s) *(please identify below)*:

Response to Notice to Comply;
Paper Copy of Sequence Listing;
CRF of Sequence Listing (11 pages); and
Copy of Notice to Comply with Sequence Requirements

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey C. Pepe, Ph.D.	00500 PATENT TRADEMARK OFFICE
Signature		
Date	7/10/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Linda M. Povinelli	
Signature		Date: 7/10/01

193937 [12/19/00]

RECEIVED
JUL 17 2001
OFFICE OF PETITIONS

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT	($)	620.00

Complete if Known	
Application Number	09/189,415
Filing Date	November 10, 1998
First Named Inventor	B. Brett Finlay
Examiner Name	S. Devi
Group Art Unit	1645
Attorney Docket No.	482112.402

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 19-1090

Deposit Account Name: Seed Intellectual Property Law Group PLLC

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 and credit any overpayment to Deposit Account Number above.

☒ Applicant claims small entity status. See 37 CFR 1.27

2. ☒ Payment Enclosed:

☒ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	
				SUBTOTAL (1)	($)

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below	=	Fee Paid
Total Claims		-** =		X		=	
Independent Claims		-** =		X		=	
Multiple Dependent				X		=	

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	** *Reissue independent claims over original patent*
110	18	210	9	** *Reissue claims in excess of 20 and over original patent*

SUBTOTAL (2) ($)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for *ex parte* reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive – unavoidable	
141	1,240	241	620	Petition to revive – unintentional	620
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	130	123	130	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify) ____					

*Reduced by Basic Filing Fee Paid SUBTOTAL (3) ($) 620

SUBMITTED BY

Name (Print/Type)	Jeffrey C. Pepe	Registration No. Attorney/Agent	46,985
Firm Name/ Address			
Signature		Date	7/10/01

00500
PATENT TRADEMARK OFFICE

168585

V. Ryan

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/189,415

Art Unit / Team No. : 1641

Date Processed by STIC: 3/10/2000

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,

2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

MARK SPENCER 703-308-4212

Application No.: 09/189,415

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- [ ] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- [ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- [ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- [X] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- [ ] 7. Other: _____

Applicant Must Provide:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Raw Sequence Listing Error Summary

ERROR DETECTED **SUGGESTED CORRECTION** **SERIAL NUMBER:** 09/189,415

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 _____ Wrapped Nucleics
The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

2 _____ Wrapped Aminos
The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

3 _____ Incorrect Line Length
The rules require that a line not exceed 72 characters in length. This includes spaces.

4 _____ Misaligned Amino Acid Numbering
The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.

5 _____ Non-ASCII
This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.

6 _____ Variable Length
Sequence(s) ____ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.

7 _____ PatentIn ver. 2.0 "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.

8 _____ Skipped Sequences (OLD RULES)
Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).

9 _____ Skipped Sequences (NEW RULES)
Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

10 J Use of n's or Xaa's (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa repre

11 _____ Use of <213>Organism (NEW RULES)
Sequence(s) _____ are missing this mandatory field or its response.

12 _____ Use of <220>Feature (NEW RULES)
Sequence(s) ____ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)

13 _____ PatentIn ver. 2.0 "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.

AKS-Biotechnology Systems Branch- 5/15/99

J. Ryan

1641

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/189,415

DATE: 03/10/2000
TIME: 15:42:36

Input Set: I189415.RAW

This Raw Listing contains the General Information Section and up to first 5 pages.

Does Not Comply
Corrected Diskette Needed

p. 2

<110> APPLICANT: Finlay, Brett B
Kenny, Brendan
DeVinney, Rebekah
Stein, Markus
<120> TITLE OF INVENTION: HOST RECEPTOR FOR PATHOGENIC BACTERIA
<130> FILE REFERENCE: 07422/013001
<140> CURRENT APPLICATION NUMBER: US/09/189,415
<141> CURRENT FILING DATE: 1998-11-10
<150> EARLIER APPLICATION NUMBER: 60/065,130
<151> EARLIER FILING DATE: 1997-11-12
<160> NUMBER OF SEQ ID NOS: 9
<170> SOFTWARE: PatentIn Ver. 2.0
<210> SEQ ID NO 1
<211> LENGTH: 1920
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 1

cggctgcata ccattacgtc atagtaatat aaaggaacgt gtcaaatttc taaataaaag 60
gatatatgta tgcctattgg taaccttggt aataatgtaa atggcaatca tttaattccc 120
cctgcgccgc cactaccttc acaaacagac ggcgcggcac ggggaggaac tggtcatcta 180
attagctcta caggagcatt aggatctcgt tcattgtttt ctcccctgag aaattctatg 240
gctgattctg tcgattccag agatattcca ggacttccta caaacccatc gaggcttgct 300
gcagctacat ctgagacatg cttgcttgga ggatttgaag ttctccatga taaggggcca 360
cttgatattc tcaatacgca aattggaccc tctgcatttc gtgttgaagt gcaggcagat 420
ggtactcatg ccgctattgg agaaaaaaat ggtttggagg ttagcgttac attaagtcct 480
caagaatgga gcagcttgca atctattgat actgagggta aaaacagatt tgtttttacc 540
gggggacgtg gcggtagtgg gcatccgatg gtcactgtcg catcagatat cgcggaagct 600
cgtacgaaaa tactggccaa attagaccca gacaatcatg gaggacgtca acccaaggac 660
gttgatacgc gttctgttgg tgttggcagc gcttcgggaa tagatgatgg cgttgttagc 720
gaaacccata cttcaacaac aaattccagc gttcgctcag atcctaaatt ctgggtttct 780
gtcggcgcaa ttgctgctgg tttagcggga ctggcggcaa ctggtattgc acaggcgttg 840
gctttgacac cggaaccgga tgatcctaca accaccgatc ctgatcaggc cgcaaatgct 900
gcagaaagtg caacaaaaga tcagttaacg caagaagcat tcaagaaccc tgagaaccag 960
aaagttaaca tcgatgcgaa cggaaatgct attccgtctg gggaattaaa agatgatatt 1020
gttgagcaaa tagcacaaca agctaaagag gctggtgagg tggccagaca gcaggctgtt 1080
gaaagcaatg cacaggcgca gcagcgatat gaggatcagc atgccagacg tcaggaggaa 1140
ttacagcttt catcgggtat tggttacggc ctcagcagtg cattgattgt tgctgggggа 1200
attggtgctg gtgtaacgac tgcgctccat agacgaaatc agccggcaga acagacaact 1260
actacaacaa cacatacggt agtgcagcaa cagaccggag ggatacccca gcacaaggtg 1320
gcactgatgc cacaagagcg aagacgcttc tctgatagac gtgattcgca ggggagtgtt 1380
gcatcgacac actggtcaga ttcctctagc gaagtggtta atccatatgc tgaagttggg 1440
ggggctcgga atagtctatc ggctcatcag ccagaagagc atatttatga tgaggtcgct 1500
gcagatcctg gttatagcgt tattcagaat ttttcaggga gcggcccagt taccggaagg 1560
ttaataggaa ctccagggca aggtatccaa agtacttatg cgcttctggc aaacagcggc 1620

ggattgcgtt taggtatggg aggattaacg agtggtggcg agacggcagt aagttctgta 1680
aatgccgcac caacgcaggg accagtacgt ttcgtttaaa tatatctgtg agtatttagt 1740
tgaggttggg gtggggtggg ggggcgtttt actagcgtta atgtttcaga gaacaacgtt 1800
gcagcatggg taactcttga acttctgtta ttataatcaa ttaagagaaa ttataatgtc 1860
atcaagatat gaacttttat tagataggtt tgcggaaaaa attggtgttg gatctatttc 1920

<210> SEQ ID NO 2
<211> LENGTH: 549
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 2

Met Pro Ile Gly Asn Leu Gly Asn Asn Val Asn Gly Asn His Leu Ile
1 5 10 15
Pro Pro Ala Pro Pro Leu Pro Ser Gln Thr Asp Gly Ala Ala Arg Gly
20 25 30
Gly Thr Gly His Leu Ile Ser Ser Thr Gly Ala Leu Gly Ser Arg Ser
35 40 45
Leu Phe Ser Pro Leu Arg Asn Ser Met Ala Asp Ser Val Asp Ser Arg
50 55 60
Asp Ile Pro Gly Leu Pro Thr Asn Pro Ser Arg Leu Ala Ala Ala Thr
65 70 75 80
Ser Glu Thr Cys Leu Leu Gly Gly Phe Glu Val Leu His Asp Lys Gly
85 90 95
Pro Leu Asp Ile Leu Asn Thr Gln Ile Gly Pro Ser Ala Phe Arg Val
100 105 110
Glu Val Gln Ala Asp Gly Thr His Ala Ala Ile Gly Glu Lys Asn Gly
115 120 125
Leu Glu Val Ser Val Thr Leu Ser Pro Gln Glu Trp Ser Ser Leu Gln
130 135 140
Ser Ile Asp Thr Glu Gly Lys Asn Arg Phe Val Phe Thr Gly Gly Arg
145 150 155 160
Gly Gly Ser Gly His Pro Met Val Thr Val Ala Ser Asp Ile Ala Glu
165 170 175
Ala Arg Thr Arg Ile Leu Ala Lys Leu Asp Pro Asp Asn His Gly Gly
180 185 190
Arg Gln Pro Lys Asp Val Asp Thr Arg Ser Val Gly Val Gly Ser Ala
195 200 205
Ser Gly Ile Asp Asp Gly Val Val Ser Glu Thr His Thr Ser Thr Thr
210 215 220
Asn Ser Ser Val Arg Ser Asp Pro Lys Phe Trp Val Ser Val Gly Ala
225 230 235 240
Ile Ala Ala Gly Leu Ala Gly Leu Ala Ala Thr Gly Ile Ala Gln Ala
245 250 255
Leu Ala Leu Thr Pro Glu Pro Asp Asp Pro Thr Thr Thr Asp Pro Asp
260 265 270
Gln Ala Ala Asn Ala Ala Glu Ser Ala Thr Lys Asp Gln Leu Thr Gln
275 280 285
Glu Ala Phe Lys Asn Pro Glu Asn Gln Lys Val Asn Ile Asp Ala Asn
290 295 300
W--> **Gly Asn Ala Ile Pro Ser Gly Glu Leu Xaa Asp Asp Ile Val Glu Gln**
305 310 315 320

All Item 10 on Error Summary Sheet

Ile Ala Gln Gln Ala Lys Glu Ala Gly Glu Val Ala Arg Gln Gln Ala
325 330 335
Val Glu Ser Asn Ala Gln Ala Gln Gln Arg Tyr Glu Asp Gln His Ala
340 345 350
Arg Arg Gln Glu Glu Leu Gln Leu Ser Ser Gly Ile Gly Tyr Gly Leu
355 360 365
Ser Ser Ala Leu Ile Val Ala Gly Gly Ile Gly Ala Gly Val Thr Thr
370 375 380
Ala Leu His Arg Arg Asn Gln Pro Ala Glu Gln Thr Thr Thr Thr Thr
385 390 395 400
Thr His Thr Val Val Gln Gln Gln Thr Gly Gly Ile Pro Gln His Lys
405 410 415
Val Ala Leu Met Pro Gln Glu Arg Arg Arg Phe Ser Asp Arg Arg Asp
420 425 430
Ser Gln Gly Ser Val Ala Ser Thr His Trp Ser Asp Ser Ser Ser Glu
435 440 445
Val Val Asn Pro Tyr Ala Glu Val Gly Gly Ala Arg Asn Ser Leu Ser
450 455 460
Ala His Gln Pro Glu Glu His Ile Tyr Asp Glu Val Ala Ala Asp Pro
465 470 475 480
Gly Tyr Ser Val Ile Gln Asn Phe Ser Gly Ser Gly Pro Val Thr Gly
485 490 495
Arg Leu Ile Gly Thr Pro Gly Gln Gly Ile Gln Ser Thr Tyr Ala Leu
500 505 510
Leu Ala Asn Ser Gly Gly Leu Arg Leu Gly Met Gly Gly Leu Thr Ser
515 520 525
Gly Gly Glu Thr Ala Val Ser Ser Val Asn Ala Ala Pro Thr Pro Gly
530 535 540
Pro Val Arg Phe Val
545

<210> SEQ ID NO 3
<211> LENGTH: 1723
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 3

atgcctattg gtaaccttgg tcataatccc aatgtgaata attcaattcc tcctgcacct 60
ccattacctt cacaaaccga cggtgcaggg gggcgtggtc agctcattaa ctctacgggg 120
ccgttgggat ctcgtgcgct atttacgcct gtaaggaatt ctatggctga ttctggcgac 180
aatcgtgcca gtgatgttcc tggacttcct gtaaatccga tgcgcctggc ggcgtctgag 240
ataacactga atgatggatt tgaagttctt catgatcatg gtccgctcga tactcttaac 300
aggcagattg gctcttcggt atttcgagtt gaaactcagg aagatggtaa acatattgct 360
gtcggtcaga ggaatggtgt tgagacctct gttgttttaa gtgatcaaga gtacgctcgc 420
ttgcagtcca ttgatcctga aggtaaagac aaatttgtat ttactggagg ccgtggtggt 480
gctgggcatg ctatggtcac cgttgcttca gatatcacgg aagcccgcca aaggatactg 540
gagctgttag agcccaaagg gaccggggag tccaaaggtg ctggggagtc aaaaggcgtt 600
ggggagttga gggagtcaaa tagcggtgcg gaaaacacca cagaaactca gacctcaacc 660
tcaacttcca gccttcgttc agatcctaaa ctttggttgg cgttggggac tgttgctaca 720
ggtctgatag ggttggcggc gacgggtatt gtacaggcgc ttgcattgac gccggagccg 780
gatagcccaa ccacgaccga ccctgatgca gctgcaagtg caactgaaac tgcgacaaga 840
gatcagttaa cgaaagaagc gttccagaac ccagataatc aaaaagttaa tatcgatgag 900

ctcggaaatg cgattccgtc aggggtattg aaagatgatg ttgttgcgaa tatagaagag 960
caggctaaag cagcaggcga agaggccaaa cagcaagcca ttgaaaataa tgctcaggcg 1020
caaaaaaaat atgatgaaca acaagctaaa cgccaggagg agctgaaagt ttcatcgggg 1080
gctggctacg gtcttagtgg cgcattgatt cttggtgggg gaattggtgt tgccgtcacc 1140
gctgcgcttc atcgaaaaaa tcagccggta gaacaaacaa caacaactac tactacaact 1200
acaactacaa gcgcacgtac ggtagagaat aagcctgcaa ataatacacc tgcacagggc 1260
aatgtagata cccctgggtc agaagatacc atggagagca gacgtagctc gatggctagc 1320
acctcgtcga ctttctttga cacttccagc atagggaccg tgcagaatcc gtatgctgat 1380
gttaaaacat cgctgcatga ttcgcaggtg ccgacttcta attctaatac gtctgttcag 1440
aatatgggga atacagattc tgttgtatat agcaccattc aacatcctcc ccgggatact 1500
actgataacg gcgcacggtt attaggaaat ccaagtgcgg ggattcaaag cacttatgcg 1560
cgtctggcgc taagtggtgg attacgccat gacatgggag gattaacggg ggggagtaat 1620
agcgctgtga atacttcgaa taacccacca gcgccgggat cccatcgttt cgtctaaata 1680
tatccataat cattttattt agagggaggg agggggggaag tct 1723

<210> SEQ ID NO 4
<211> LENGTH: 559
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 4

Met Pro Ile Gly Asn Leu Gly His Asn Pro Asn Val Asn Asn Ser Ile
1 5 10 15
Pro Pro Ala Pro Pro Leu Pro Ser Gln Thr Asp Gly Ala Gly Gly Arg
20 25 30
Gly Gln Leu Ile Asn Ser Thr Gly Pro Leu Gly Ser Arg Ala Leu Phe
35 40 45
Thr Pro Val Arg Asn Ser Met Ala Asp Ser Gly Asp Asn Arg Ala Ser
50 55 60
Asp Val Pro Gly Leu Pro Val Asn Pro Met Arg Leu Ala Ala Ser Glu
65 70 75 80
Ile Thr Leu Asn Asp Gly Phe Glu Val Leu His Asp His Gly Pro Leu
85 90 95
Asp Thr Leu Asn Arg Gln Ile Gly Ser Ser Val Phe Arg Val Glu Thr
100 105 110
Gln Glu Asp Gly Lys His Ile Ala Val Gly Gln Arg Asn Gly Val Glu
115 120 125
Thr Ser Val Val Leu Ser Asp Gln Glu Tyr Ala Arg Leu Gln Ser Ile
130 135 140
Asp Pro Glu Gly Lys Asp Lys Phe Val Phe Thr Gly Gly Arg Gly Gly
145 150 155 160
Ala Gly His Ala Met Val Thr Val Ala Ser Asp Ile Thr Glu Ala Arg
165 170 175
Gln Arg Ile Leu Glu Leu Leu Glu Pro Lys Gly Thr Gly Glu Ser Lys
180 185 190
Gly Ala Gly Glu Ser Lys Gly Val Gly Glu Leu Arg Glu Ser Asn Ser
195 200 205
Gly Ala Glu Asn Thr Thr Glu Thr Gln Thr Ser Thr Ser Thr Ser Ser
210 215 220
Leu Arg Ser Asp Pro Lys Leu Trp Leu Ala Leu Gly Thr Val Ala Thr
225 230 235 240
Gly Leu Ile Gly Leu Ala Ala Thr Gly Ile Val Gln Ala Leu Ala Leu

```
195                 245                 250                 255
196     Thr Pro Glu Pro Asp Ser Pro Thr Thr Thr Asp Pro Asp Ala Ala Ala
197                 260                 265                 270
198     Ser Ala Thr Glu Thr Ala Thr Arg Asp Gln Leu Thr Lys Glu Ala Phe
199             275                 280                 285
200     Gln Asn Pro Asp Asn Gln Lys Val Asn Ile Asp Glu Leu Gly Asn Ala
201         290                 295                 300
202     Ile Pro Ser Gly Val Leu Lys Asp Asp Val Val Ala Asn Ile Glu Glu
203     305                 310                 315                 320
204     Gln Ala Lys Ala Ala Gly Glu Glu Ala Lys Gln Gln Ala Ile Glu Asn
205                 325                 330                 335
206     Asn Ala Gln Ala Gln Lys Lys Tyr Asp Glu Gln Gln Ala Lys Arg Gln
207                 340                 345                 350
208     Glu Glu Leu Lys Val Ser Ser Gly Ala Gly Tyr Gly Leu Ser Gly Ala
209             355                 360                 365
210     Leu Ile Leu Gly Gly Gly Ile Gly Val Ala Val Thr Ala Ala Leu His
211         370                 375                 380
212     Arg Lys Asn Gln Pro Val Glu Gln Thr Thr Thr Thr Thr Thr Thr Thr
213     385                 390                 395                 400
214     Thr Thr Thr Ser Ala Arg Thr Val Glu Asn Lys Pro Ala Asn Asn Thr
215                 405                 410                 415
216     Pro Ala Gln Gly Asn Val Asp Thr Pro Gly Ser Glu Asp Thr Met Glu
217                 420                 425                 430
218     Ser Arg Arg Ser Ser Met Ala Ser Thr Ser Ser Thr Phe Phe Asp Thr
219             435                 440                 445
220     Ser Ser Ile Gly Gly Pro Cys Arg Ile Arg Met Leu Met Leu Lys His
221         450                 455                 460
222     Arg Cys Met Ile Arg Arg Cys Arg Leu Leu Ile Leu Ile Arg Leu Phe
223     465                 470                 475                 480
224     Arg Ile Trp Gly Ile Gln Ile Ser Val Val Tyr Ser Thr Ile Gln His
225                 485                 490                 495
226     Pro Pro Arg Asp Thr Thr Asp Asn Gly Ala Arg Leu Leu Gly Asn Pro
227                 500                 505                 510
228     Ser Ala Gly Ile Gln Ser Thr Tyr Ala Arg Leu Ala Leu Ser Gly Gly
229             515                 520                 525
230     Leu Arg His Asp Met Gly Gly Leu Thr Gly Gly Ser Asn Ser Ala Val
231         530                 535                 540
232     Asn Thr Ser Asn Asn Pro Pro Ala Pro Gly Ser His Arg Phe Val
233     545                 550                 555
234 <210> SEQ ID NO 5
235 <211> LENGTH: 1460
236 <212> TYPE: DNA
237 <213> ORGANISM: Escherichia coli
238 <400> SEQUENCE: 5
239     aattctgttg ctgatgctgc tgattctcgt gccagtgata ttcccggact tcctacaaat 60
240     ccactgcgct ttgctgcgtc cgaggtatct ttgcatggtg cgcttgaagt tcttcatgat 120
241     aaaggggggc ttgatactct taactctgct attggatctt cgttattccg tgttgaaact 180
242     cgggatgatg gcagccatgt tgctatcggg caaaaaaatg gcctcgagac cactgttgtt 240
243     ttaagtgagc aagagttttc tagcttacag tcccttgatc ctgaaggtaa aaacaaattt 300
244     gtatttactg gaggccgcgg tggcccaggg catgctatgg tcacggttgc ttcagatatc 360
```

VERIFICATION SUMMARY
PATENT APPLICATION **US/09/189,415**

DATE: 03/10/2000
TIME: 15:42:36

Input Set: **I189415.RAW**

Line	?	Error/Warning	Original Text
93	W	"N" or "Xaa" used: Feature required	Gly Asn Ala Ile Pro Ser Gly Glu Leu Xaa A